Small molecule corticotropin-releasing factor antagonists

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 11, 2002, Pages 1619-1630

  Lanier, Marion ^a   Williams, John P ^a  

^a NEUROCRINE BIOSCIENCES INC   (United States)

Author keywords

Antagonist; Anxiety; Corticotropin releasing factor (CRF); Depression; Stress

Indexed keywords

4 (2 CHLORO 4 METHOXY 5 METHYLPHENYL) N [2 CYCLOPROPYL 1 (3 FLUORO 4 METHYLPHENYL)ETHYL] 5 METHYL N (2 PROPYNYL) 2 THIAZOLAMINE; AMIDE; ANTALARMIN; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; METHANOL DERIVATIVE; NEUROHORMONE; PEPTIDE HORMONE; PIPERIDONE DERIVATIVE; PYRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRAZOLONE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRIMIDINONE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE; THIAZOLE DERIVATIVE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; AUTONOMIC NERVOUS SYSTEM; BEHAVIOR; DEPRESSION; DRUG STRUCTURE; ENDOCRINE SYSTEM; IMMUNE SYSTEM; MEDICAL LITERATURE; MODULATION; MOLECULAR WEIGHT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PATENT; PROTEIN INTERACTION; REVIEW; STRESS; X RAY ANALYSIS;

EID: 0036849729     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.11.1619     Document Type: Review

References (35)

1. ARBORELIUS L, OWENS MJ, PLOTSKY PM, NEMEROFF CB: The role of corticotropin-releasing factor in depression and anxiety disorders. J. Endocrinol. (1999) 160:1-12.
2. HOLSBOER F: Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. J. Affect. Disord. (2001) 62(1-2):77-91.
3. TIMPLE P, SPANAGEL R, SILLAGEL I et al.: Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nature Genet. (1998) 19:162-166.
4. BALE TL, CONTARINO A, SMITH GW et al.: Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nature Genet. (2000) 24(4):410-414.
5. NEMEROFF CB, WIDERLOV E, BISSETTE G et al.: Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science (1984) 226(4680):1342-1344.
6. HOLSBOER F; VON BARDELEBEN U, GERKEN A, STALLA GK, MULLER OA: Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. N. Engl. J. Med. (1984) 311(17):1127.
7. GRIGORIADIS DE, HADDACH M, LING N, SAUNDERS J: The CRF receptor: structure, function and potential for therapeutic intervention. Curr. Med. Chem.-Central Nervous system agents (2001) 1:63-97.
8. GILLIGAN PJ, ROBERTSON DW, ZACZEK R: Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents. J. Med. Chem. (2000) 43(9):1641-1660.
9. HOLSBOER F: The rational for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J. Psychiatr. Res. (1999) 33:181-214.
10. TACHE Y, MARTINEZ V, MILLION M, WANG L: Stress and the gastrointestinal tract III. Stress-related alterations of gut motor function: role of brain corticotropin-releasing factor receptors. Am. J. Physiol. Gastrointest. Liver Physiol. (2001) 280(2):G173-G177.
11. KOOB G: Neurobiology of addiction. Toward the development of new therapies. Ann. NY Acad Sci. (2000) 909:170-85.
12. LARIVIERE WR, MELZACK R. The role of corticotropin-releasing factor in pain and analgesia. Pain (2000) 84:1-12.
13. SKELTON KH, OWENS MJ, NEMEROFF CB: The neurobiology of urocortin. Regul. Pept. (2000) 93(1-3):85-92.
14. GULLY D, GESLIN M, SERVA L et al.: 4-(2-Chloro-4- methoxy-5-methylphenyl)- N-[(1S)-2-cyclopropyl- 1-(3-fluoro-4-methylphenyl) ethyl]5-methyl-N-( 2-propynyl)-1,3- thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotropin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization. J.. Pharmacol. Exp. Ther. (2002) 301(1):322-332.
15. LIAW CW, GRIGORIADIS DE, LORANG MT, DE SOUZA EB, MAKI RA: Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Mol. Endocrinology (1997) 11:2048-2053.
16. GRIEBEL G, SIMIAND J, STEINBERG R et al.: 4-(2-Chloro-4- methoxy-5-methylphenyl)- N-[(1S)-2-cyclopropyl- 1-(3-fluoro-4-methylphenyl) ethyl]5-methyl-N-( 2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotropin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J. Pharmacol. Exp. Ther. (2002) 301(1):333-345.
17. 1) receptor antagonist activities. Bioorg. Med. Chem. Lett. (2001) 11(24):3165-3168.
18. KELLER PA, BOWMAN M, DANG KH et al.: Pharmacophore development for corticotropin-releasing hormone: new insights into inhibitor activity. J. Med. Chem. (1999) 42:2351-2357.
19. WANG XC, SAUNDERS J: Design and discovery of nonpeptide antagonists for corticotropin-releasing factor receptor: neurocrine multichannel discovery approach. 221st National ACS meeting, San Diego, USA (2001). MEDI 207.
20. CHEN YL, MANSBACH RS, WINTER SM et al.: Synthesis and oral efficacy of a 4-(butylethylamino)pyrolo[2,3D]pyrimidine: A centrally active corticotropin-releasing factor1 receptor antagonist. J. Med. Chem. (1997) 40:1749-1754.
21. ARVANITIS AG, GILLIGAN PJ, CHORVAT RS et al.: nonpeptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines. J. Med. Chem. (1999) 42:805-818.
22. 1 receptor antagonists. J. Med. Chem. (1996) 39:4358-4360.
23. COCUZZA AJ, HOBBS FW, ARNOLD CR et al.: 4-aryl-2-anilinopyrimidnes as corticotropin-releasing hormone (CRH) antagonists. Bioorg. Med. Chem. Letters (1999) 9:1057-1062.
24. OKUYAMA S, CHAKI S, KAWASHIMA N et al.: Receptor binding, behavioural and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. J. Pharmacol. Exp. Ther. (1999) 289(2):926-935.
25. GILLIGAN PJ, HE L, CULP S, FITZGERALD L, TAM SW, WONG YN: Structure-activity studies on 4-substituted-2-anilinopyrimidine corticotropin releasing factor (CRF) antagonists. Bioorg. Med. Chem. (1999) 7:2321-2328.
26. HODGE CN, ALDRICH PE, WASSERMAN ZR et al.: Corticotropin-releasing hormone receptor antagonists: framework design and synthesis guided by ligand conformational studies. J. Med. Chem. (1999) 42:819-832.
27. 1 receptor binding and lipophilicity of pyrrolpyrimidines, potential nonpeptide corticotropin-releasing hormone Type 1 receptor antagonists. Bioorg. Med. Chem. (2002) 10:175-183.
28. WILSON DM, TERMIN AP, MAO L et al.: Arylamidrazones as novel corticotropin releasing factor receptor antagonists. J Med. Chem. (2002) 45(11):2123-2126.
29. VALE W, SPEISS J, RIVIER C, RIVIER J: Characterization of a 41 residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β endorphin. Science (1981) 213 (4514):1394-1397.
30. REYES TM, LEWIS K, PERRIN MH et al.: Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by Type 2 CRF receptors. Proc. Natl. Acad. Sci. USA (2001) 98(5)-2843-2848.
31. RUHMANN A, BONK I, LIN CR, ROSENFELD MG, SPIESS J: Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2β-selective antisauvagine-30. Proc. Natl. Acad. Sci. USA. (1998) 95(26):15264-15269.
32. HSU SY, HSUEH AJ: Human stresscopin and stresscopin-related peptide are selective ligands for the Type 2 corticotropin-releasing hormone receptor. Nat. Med. (2001) 7(5):605-611.
33. OWENS MJ, NEMEROFF CB: Corticotropin-releasing factor antagonists. Therapeutic potential in the treatment of affective disorders. CNS drugs (1999) 12(2):85-92.
34. KECK ME, WELT T, WIGGER A et al.: The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats. Eur. J. Neurosci. (2001) 13(2):373-380.
35. ZOBEL AW, NICKEL T, KUNZEL HE et al.: Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. (2000) 34(3):171-181.